Company News: Anergis Appoints Jacques-François Martin as Chairman of the Board of Directors
Anergis, a clinical-stage biopharmaceutical company developing novel allergy vaccines, today announced the appointment of Jacques-François Martin, Chairman and CEO of vaccine company Mymetics, as Chairman of the Board of Directors.
Anergis develops allergy vaccines based on its proprietary technology of “Contiguous Overlapping Peptides” (“COPs”). Anergis’ lead allergy vaccine, called “AllerT”, is in clinical Phase IIb development and is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widespread condition in developed countries. Anergis’ vaccines are designed to provide long-term protection against allergies with a 2-month treatment.
Jacques-François Martin is Chairman and CEO of Mymetics Corporation. Previously, he was CEO of Chiron Vaccines (now Novartis) from 1991 to 1993 and CEO of Pasteur-Mérieux (now Sanofi-Pasteur) from 1988 to 1991. In addition, he held leadership positions with not‐for‐profit organizations dedicated to the development of vaccines for debilitating and life-threatening diseases in both developed nations and third world countries. Among others, he was the first President and CEO of The Vaccine Fund (Bill and Melinda Gates Foundation) from 2000 to January 2005 and a member of the Board of the International AIDS Vaccine Initiative (IAVI) from November 1997 to June 2003. He started his executive career as Chief Executive Officer of Rhône-Poulenc Pharma in Hamburg, Germany, in 1970. Mr. Martin is a member of the French Academy of Technologies and an officer in the French Order of Merit.